Immuno-Oncology - New Developments in Solid Tumor therapy will be discussed by Celgene at the London Cancer Congress.

Celgene will present at the Cancer Diagnosis and Therapy Congress to be held on 3 – 4 September 2015 in London, UK

Speaker: Stefan Gluck - Vice President, Global Medical Affairs; Breast, Ovarian Cancer and Immunotherapy - Celgene

Topic: Immuno-Oncology - New Developments in Solid Tumor therapy

Talking about the latest developments in solid tumor therapy, Prof. Gluck said, “Solid Tumor Systemic Therapy was dominated over several decades by cytotoxic chemotherapy. Only few selected tumors were treated with targeted therapy e.g., anti-hormone approaches if estrogen receptor was identified as a biological target and later on with human epidermal growth factor receptors as targets. Only occasionally immunotherapy in the form of vaccination was available. Recently through better molecular understanding of the immune system, immuno therapy has begun to emerge and now there are several compounds in the market”. He further added, “These treatments helped in two ways to improve outcome in some selected solid tumors; prolonging effect of treatment including survival and reducing or avoiding toxicity of cytotoxic therapy”.

Bringing together more than 150 experts from industry, research laboratories, hospitals, device and diagnostic manufacturers and academia in the field of cancer research, the congress will be an excellent opportunity to meet and network with industry peers and share experiences. Download brochure for more information about the programme.

Other speakers at the congress:

  • Celgene, USA
  • Agenus 4-Antibody AG, Switzerland
  • Imperial College London, UK
  • Wolfgang Goethe-University, Germany
  • Queen’s University Belfast, UK
  • APeX Disease Reserch Institute, USA
  • University of Manchester, UK
  • Nanomerics Ltd, UK
  • Guangzhou East Cancer Hospital, China
  • Metropolitan Hospital, Greece
  • Cancer Science Institute of Singapore, Singapore
  • University of Buenos Aires, Argentina
  • Valdarno Hospital, Italy

The two day congress will have two streams and will cover topics such as

  • Nano-enabled delivery of cancer therapies
  • Interventional oncological therapies in the treatment of liver metastases
  • Molecular targeted therapeutics
  • Electrochemical biosensors for prostate cancer diagnosis
  • NGS and bioinformatics for cancer immunotherapies
  • Repurposing FDA-approved drugs to eradicate cancer stem cells across multiple tumour types
  • Epigenetic drivers of drug resistance

For information on registrations or sponsorship packages mail
Call us on +9120 6704 6819 for registration details.
We look forward to meeting you in London!

Warm Regards,
Oliver Smith
Marketing Manager | MnM Conferences